Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
28. Februar 2019 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering
06. Februar 2019 00:15 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
05. Februar 2019 17:15 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
11. Dezember 2018 16:05 ET
|
Aeglea BioTherapeutics, Inc.
Single, Global Pivotal Trial to Support Registration; Primary Endpoint of Arginine Reduction Expected to Initiate in Q2 2019; Topline Data Anticipated in Q1 2021 Company to Host Conference Call...
Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference
06. Dezember 2018 16:05 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference
20. November 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
08. November 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics to Present Preclinical Data on a New Pipeline Therapeutic for Cystinuria in an Oral Presentation at the 2018 American Society of Nephrology (ASN) Annual Meeting
26. Oktober 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AEB5100 is an Engineered Human Enzyme with Novel Cystine Degrading Activity Presentation Today at 5:54 p.m. PT at the 2018 American Society of Nephrology (ASN) Annual Meeting AUSTIN, Texas, Oct. ...
Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress
22. Oktober 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
Pegzilarginase Monotherapy Demonstrates Anti-Tumor Activity AUSTIN, Texas, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company...
Aeglea BioTherapeutics to Present Preclinical Data on New Pipeline Therapeutic for Homocystinuria at 2018 American Society of Human Genetics (ASHG) Conference
19. Oktober 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AEB4104 is a Novel Engineered Human Enzyme with Unique Specificity for Degrading Both Homocysteine and Homocystine AEB4104 Prevents Death, Stops Disease Progression, and Reverses Liver Pathology in a...